China's Innovative Drug Approvals Hit a Record High in 2025

A Record Year for New Medicines

China approved a record number of innovative drugs in 2025 — 76 in total, up sharply from 48 the year before, according to national drug regulators. The figure marks a new high and includes a mix of chemical drugs, biologics, and traditional medicines, with 11 classified as first-in-class therapies featuring entirely novel treatment mechanisms.

For international patients considering care in China, this trend has a direct and practical meaning: more of the world's newest treatments are becoming available, and they are reaching patients faster than before.

Why Access Is Accelerating

Several policy reforms have shortened the path from approval to the bedside. Regulators have streamlined review processes and expanded programs designed to bring innovative therapies to patients sooner. The result is a steadily widening range of options across major disease areas, including oncology, autoimmune and immune-related conditions, cardiovascular disease, and metabolic and neurological disorders.

The expansion is not limited to domestically developed drugs. Imported innovative medicines are also reaching Chinese hospitals more quickly, narrowing the gap that international patients once faced between a therapy's global launch and its availability in China.

The Greater Bay Area Pathway

One of the most important channels for international patients is the Guangdong-Hong Kong-Macao Greater Bay Area "Hong Kong and Macao Drug and Device Connect" policy. The program allows designated hospitals to use selected innovative drugs and devices already approved in Hong Kong and Macao, ahead of their broader availability on the mainland. By late 2025, the program had introduced well over a hundred drugs and devices and recorded more than ten thousand patient visits, with the network of designated hospitals continuing to expand.

What This Means for International Patients

Among the hospitals participating in these innovation pathways are leading private international hospitals that serve cross-border patients, including those in the United Family Healthcare network. These institutions combine access to newly approved therapies with internationally aligned standards of care and multilingual support — a combination that matters when navigating complex treatment far from home.

As always, whether a specific therapy is appropriate depends on each patient's individual situation. Patients are encouraged to consult directly with a qualified specialist to understand which options may be available and suitable for their care.

Sources: Xinhua — 2025 drug approvals · Nature — NMPA 2025 approvals